LENZ THERAPEUTICS ($LENZ) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of -$0.53 per share, beating estimates of -$0.56 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $LENZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LENZ THERAPEUTICS Hedge Fund Activity
We have seen 55 institutional investors add shares of LENZ THERAPEUTICS stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 770,455 shares (+inf%) to their portfolio in Q4 2024, for an estimated $22,243,035
- PRICE T ROWE ASSOCIATES INC /MD/ added 374,326 shares (+83.4%) to their portfolio in Q4 2024, for an estimated $10,806,791
- ECOR1 CAPITAL, LLC removed 346,772 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $10,011,307
- SAMSARA BIOCAPITAL, LLC removed 221,492 shares (-18.3%) from their portfolio in Q4 2024, for an estimated $6,394,474
- STATE STREET CORP added 205,162 shares (+71.0%) to their portfolio in Q4 2024, for an estimated $5,923,026
- PARKMAN HEALTHCARE PARTNERS LLC removed 139,357 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,023,236
- SCHONFELD STRATEGIC ADVISORS LLC removed 107,300 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,097,751
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
